Fidia Farmaceutici, an Italian pharmaceutical company focused on the research, development and manufacturing of hyaluronic acid-based products, will introduce Hymovis at the annual meeting of the American Academy of Orthopaedic Surgeons in Orlando, March 1 to March 5.
Here are five things to know:
1. Hymovis is a next-generation of HA-based intra-articular therapy indicated for the treatment of pain in osteoarthritis of the knee in patients.
2. Scientists from Fidia Farmaceutici and the research group led by Lawrence Bonassar, PhD, professor in the Meinig School of Biomedical Engineering at Cornell University in Ithaca, N.Y., worked together to verify the optimal lubricating characteristics of the HA derivative.
3. Hymovis was bioengineered using a proprietary process that results in a natural hyaluronan similar to the hyaluronan found in the synovial fluid present in human joints.
4. Worldwide, hyaluronic acid-based intra-articular injections are used in the treatment of knee pain due to osteoarthritis of the knee.
5. The FDA gave premarket approval for Hymovis on Aug. 28, 2015, and it will become commercially available in March 2016.